TrialPloS one2024

Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.

Naveen Garg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.